|
1
|
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
|
J Natl Cancer Inst
|
2012
|
1.72
|
|
2
|
Acute renal infarction: a case series.
|
Clin J Am Soc Nephrol
|
2012
|
1.68
|
|
3
|
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era.
|
Nephron Physiol
|
2006
|
1.51
|
|
4
|
Renal involvement in Castleman disease.
|
Nephrol Dial Transplant
|
2010
|
1.13
|
|
5
|
Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study.
|
BMC Nephrol
|
2011
|
1.03
|
|
6
|
Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin).
|
Dermatology
|
2009
|
0.97
|
|
7
|
Sirolimus--challenging current perspectives.
|
Ther Drug Monit
|
2006
|
0.92
|
|
8
|
Serum procalcitonin in systemic autoimmune diseases--where are we now?
|
Semin Arthritis Rheum
|
2010
|
0.91
|
|
9
|
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.
|
Crit Rev Oncol Hematol
|
2011
|
0.84
|
|
10
|
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.
|
Invest New Drugs
|
2011
|
0.83
|
|
11
|
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2009
|
0.82
|
|
12
|
QT interval prolongation among patients treated with angiogenesis inhibitors.
|
Target Oncol
|
2009
|
0.81
|
|
13
|
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
|
Nephrol Dial Transplant
|
2004
|
0.78
|
|
14
|
[Angiogenesis and renal cell carcinoma].
|
Bull Cancer
|
2007
|
0.78
|
|
15
|
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
|
Oncology
|
2015
|
0.75
|
|
16
|
Reversible cardiogenic shock following 5-fluorouracil infusion.
|
Invest New Drugs
|
2009
|
0.75
|
|
17
|
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
|
J Med Virol
|
2007
|
0.75
|
|
18
|
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.
|
Invest New Drugs
|
2009
|
0.75
|
|
19
|
Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.
|
Invest New Drugs
|
2009
|
0.75
|
|
20
|
[Is dialysis efficient in the prevention of ionic contrast agent-induced nephropathy?].
|
Presse Med
|
2005
|
0.75
|
|
21
|
[Anticancer drug-induced nephrotoxicity].
|
Nephrol Ther
|
2005
|
0.75
|
|
22
|
Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders.
|
Nephrol Dial Transplant
|
2011
|
0.75
|